Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380546 | 1.00 | TSHR (0.31) | TSHRTDP1FFAR3ALDH1A1 | |
| SCHEMBL1709302 | 0.76 | MMP1 (0.33) | — | |
| SCHEMBL12374968 | 0.74 | PRKCA (0.30) | — | |
| SCHEMBL667279 | 0.74 | OR51E2 (0.39) | TSHRALDH1A1 | |
| SCHEMBL13316605 | 0.74 | OR51E2 (0.39) | TSHRALDH1A1 | |
| SCHEMBL1709280 | 0.73 | MAPK1 (0.41) | — | |
| SCHEMBL1705294 | 0.72 | PRKCA (0.33) | TSHR | |
| SCHEMBL12788693 | 0.72 | KDM4C (0.40) | TSHRALDH1A1 | |
| SCHEMBL14038364 | 0.72 | HDAC2 (0.42) | TSHRALDH1A1 | |
| SCHEMBL1709281 | 0.70 | CYP2D6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | TSHR 4867/4885TDP1 2731/4885FFAR3 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.